Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 20 de 1668 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen

Se ha producido un error durante la generación de la página

. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103213]
2. Cita con resumen
Azzouz B, Morel A, Kanagaratman L, Herlem E, Trenque T. Psoriasis after exposure to angiotensin-converting enzyme inhibitors: French pharmacovigilance data and review of the literature. Drug Saf 2019;42:diciembre. [Ref.ID 103209]
3. Cita con resumen
Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. International Journal of Medical Sciences 2019;16:julio. [Ref.ID 103207]
4. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
6.Enlace a cita original Cita con resumen
Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte JR, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Workshop on the Italian pharmacovigilance system in the international context: critical issues and perspectives. Drug Saf 2019;42:mayo. [Ref.ID 103115]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
9.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Hu OHY, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:5 de diciembre. [Ref.ID 102894]
11.Enlace a cita original Cita con resumen
Nguyen TTH, Roussin A, Rousseau A, Montastruc J-L, Montastruc F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: A pharmacoepidemiological–pharmacodynamic study in VigiBase®. Drug Saf 2018;41:noviembre. [Ref.ID 102840]
12. Cita con resumen
Anónimo. FDA warns SGLT2 inhibitors can cause flesh-eating genitali infection. DIA Daily 2018:1. [Ref.ID 102830]
13. Cita con resumen
Anónimo. Vicks vaporub: les risques des dérivés terpéniques. Prescrire 2018;38:511. [Ref.ID 102759]
15. Cita con resumen
Anónimo. Artemisia annua soft gel capsules: Reports of liver damage. New Zealand. WHO Drug Information 2018;32:20. [Ref.ID 102624]
16. Cita con resumen
Anónimo. Atezolizumab: Myocarditis. Canada. WHO Drug Information 2018;32:19. [Ref.ID 102622]
17. Cita con resumen
Anónimo. Teriparatide: Shock and loss of consciousness. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102621]
18.Enlace a cita original Cita con resumen
Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]
20. Cita con resumen
Anónimo. Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis. ISMP Quarter Watch 2018:6. [Ref.ID 102509]
Seleccionar todas
 
 1 a 20 de 1668 siguiente >>